@article{c7ab96026e4c438d9824d7a0dfb9b6ae,
title = "Development of encorafenib for BRAF-mutated advanced melanoma.",
keywords = "ADVANCED BRAF(V600)-MUTANT MELANOMA, RANDOMIZED CONTROLLED-TRIAL, DABRAFENIB PLUS TRAMETINIB, MAPK PATHWAY ACTIVATION, METASTATIC MELANOMA, OPEN-LABEL, INHIBITOR RESISTANCE, MUTANT MELANOMA, PHASE-3 TRIAL, DOUBLE-BLIND",
author = "Peter Koelblinger and Olaf Thuerigen and Reinhard Dummer",
note = "K{\"o}lblinger: Department of Dermatology, Paracelsus Medical University, Salzburg, Austria",
year = "2018",
language = "English",
volume = "30",
pages = "125--133",
journal = "CURRENT OPINION IN ONCOLOGY",
issn = "1040-8746",
publisher = "Lippincott Williams \& Wilkins ",
number = "2",
}